Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 63
Filter
1.
Sci Total Environ ; 691: 124-134, 2019 Nov 15.
Article in English | MEDLINE | ID: mdl-31319250

ABSTRACT

Permafrost thaw subjects previously frozen soil organic carbon (SOC) to microbial degradation to the greenhouse gases carbon dioxide (CO2) and methane (CH4). Emission of these gases constitutes a positive feedback to climate warming. Among numerous uncertainties in estimating the strength of this permafrost carbon feedback (PCF), two are: (i) how mineralization of permafrost SOC thawed in saturated anaerobic conditions responds to changes in temperature and (ii) how microbial communities and temperature sensitivities change over time since thaw. To address these uncertainties, we utilized a thermokarst-lake sediment core as a natural chronosequence where SOC thawed and incubated in situ under saturated anaerobic conditions for up to 400 years following permafrost thaw. Initial microbial communities were characterized, and sediments were anaerobically incubated in the lab at four temperatures (0 °C, 3 °C, 10 °C, and 25 °C) bracketing those observed in the lake's talik. Net CH4 production in freshly-thawed sediments near the downward-expanding thaw boundary at the base of the talik were most sensitive to warming at the lower incubation temperatures (0 °C to 3 °C), while the overlying sediments which had been thawed for centuries had initial low abundant methanogenic communities (< 0.02%) and did not experience statistically significant increases in net CH4 production potentials until higher incubation temperatures (10 °C to 25 °C). We propose these observed differences in temperature sensitivities are due to differences in SOM quality and functional microbial community composition that evolve over time; however further research is necessary to better constrain the roles of these factors in determining temperature controls on anaerobic C mineralization.

2.
Acta Gastroenterol Belg ; 81(3): 415-418, 2018.
Article in English | MEDLINE | ID: mdl-30350531

ABSTRACT

BACKGROUND AND STUDY AIMS: Constipation and fecal incontinence are common problems in neurologically impaired children. This paper aims to give an overview on bowel problems in cerebral palsy children and to suggest a stepwise treatment approach. A pubmed search was performed looking at studies during the past 20 years investigating bowel problems in neurologically disabled children. RESULTS: The search revealed 15 articles. Prevalence and presentation was the subject of 8 papers, confirming the importance of the problem in these children. The other papers studied the results of different treatment modalities. No significant differences between treatment modalities could be demonstrated due to small studied cohorts. Therefore, no specific treatment strategy is currently available. An experienced based stepwise approach is proposed starting with normalization of fiber intake. The evaluation of the colon transit time could help in deciding whether desimpaction and eventually laxatives including both osmotic (lactulose, macrogol) as well as stimulant laxatives might be indicated. Or, in case of fast transit loperamide or psyllium can be tried. Surgery should be a last resort option. CONCLUSION: Studies investigating constipation and continence in neurologically impaired children are scarce, making it difficult to choose for the optimal treatment. A stepwise treatment approach is proposed, measuring the colon transit time to guide treatment choices.


Subject(s)
Cerebral Palsy/epidemiology , Constipation/epidemiology , Fecal Incontinence/epidemiology , Antidiarrheals/therapeutic use , Cathartics/therapeutic use , Child , Constipation/drug therapy , Constipation/physiopathology , Fecal Incontinence/drug therapy , Fecal Incontinence/physiopathology , Gastrointestinal Agents/therapeutic use , Gastrointestinal Transit , Humans , Lactulose/therapeutic use , Laxatives/therapeutic use , Loperamide/therapeutic use , Polyethylene Glycols/therapeutic use , Prevalence , Psyllium/therapeutic use
3.
Phys Rev E ; 94(1-1): 013203, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27575226

ABSTRACT

Fundamental properties of warm dense matter are described by the dielectric function, which gives access to the frequency-dependent electrical conductivity; absorption, emission, and scattering of radiation; charged particles stopping; and further macroscopic properties. Different approaches to the dielectric function and the related dynamical collision frequency are compared in a wide frequency range. The high-frequency limit describing inverse bremsstrahlung and the low-frequency limit of the dc conductivity are considered. Sum rules and Kramers-Kronig relation are checked for the generalized linear response theory and the standard approach following kinetic theory. The results are discussed in application to aluminum, xenon, and argon plasmas.

4.
Eur Psychiatry ; 30(4): 441-7, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25891263

ABSTRACT

BACKGROUND: Little is known about how daily life mood reactivity to minor stressors (stress reactivity) might change following major depressive disorder (MDD) treatment. We investigate whether (i) mood states and appraisals of daily stressors change after treatment; (ii) stress reactivity to event, activity, or social stress differs; (iii) stress reactivity depends on severity of residual depressive symptoms; and (iv) stress reactivity in individuals with remitted or non-remitted depression differ from that of never-depressed individuals. METHODS: Thirty depressed individuals participated in an experience sampling study before and after a treatment period of 18 months; 39 healthy individuals formed a comparison group. Reactivity of positive affect (PA) and negative affect (NA) to daily stressors were measured. RESULTS: More residual symptoms were associated with larger NA responses to stress. Compared to healthy controls, participants with non-remitted MDD showed higher NA-reactivity to all stressors. In contrast, stress reactivity to event and activity stressors was normalized in remitted patients. However, they still showed heightened NA-reactivity to social stress. CONCLUSIONS: Greater stress reactivity to event and activity stress appears to be state-dependent. The heightened social stress reactivity in remitted patients suggests that sensitivity to social stress may reflect an underlying vulnerability in MDD.


Subject(s)
Activities of Daily Living/psychology , Depression/psychology , Stress, Psychological/psychology , Adult , Depression/epidemiology , Female , Humans , Male , Middle Aged , Risk Factors , Stress, Psychological/epidemiology
5.
Osteoporos Int ; 26(2): 521-9, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25209410

ABSTRACT

SUMMARY: More than 45 % of long-term childhood cancer survivors (CCS) were diagnosed with osteopenia. Our data suggest that greater awareness for osteopenia is warranted in long-term CCS, especially in survivors who are older than 30 years, male, and underweight and were treated with cranial-spinal radiotherapy and/or steroids. INTRODUCTION: Osteopenia is a potential complication of childhood cancer treatment, but the magnitude of this problem in survivors is unknown. We examined (determinants of) bone mineral density (BMD) status in long-term survivors of adult childhood cancer. METHODS: This retrospective single-centre cohort study included 346 subjects with the most common types of childhood cancer. Subjects had a median age at diagnosis of 7.0 years (range 0.1-16.8 years), a median age at follow-up of 24.5 years (range 18.0-47.6 years) and a median follow-up time of 16.7 years (range 5.6-39.9 years). Total body BMD (BMDTB) and BMD of the lumbar spine (BMDLS) were measured by dual X-ray absorptiometry. Osteopenia was defined as BMD standardized deviation score (SDS) below -1. RESULTS: Survivors had a lower BMDTB and BMDLS (mean SDS -0.55; p<0.001 and -0.30; p<0.001, respectively) as compared to healthy peers. Osteopenia (BMDTB and/or BMDLS) was present in 45% of the survivors. Multivariate logistic regression analyses identified age at diagnosis<12 years, age>30 years at follow-up, male gender, underweight at follow-up and treatment with cranial-spinal radiotherapy or prednisone as independent prognostic factors for osteopenia. CONCLUSIONS: This large cohort of childhood cancer survivors identified osteopenia in 45% of CCS. This indicates that greater awareness is warranted, especially in survivors who are older than 30 years, male, have underweight and were treated with cranial-spinal radiotherapy and/or steroids.


Subject(s)
Bone Diseases, Metabolic/diagnostic imaging , Neoplasms/therapy , Absorptiometry, Photon , Adolescent , Adult , Bone Density/physiology , Bone Diseases, Metabolic/complications , Child , Child, Preschool , Female , Humans , Infant , Lumbar Vertebrae/diagnostic imaging , Male , Middle Aged , Neoplasms/complications , Retrospective Studies , Risk Factors , Survivors , Treatment Outcome , Young Adult
6.
Pharmacogenomics J ; 15(3): 248-54, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25348617

ABSTRACT

Methotrexate (MTX) is an effective and toxic chemotherapeutic drug in the treatment of pediatric acute lymphoblastic leukemia(ALL). In this prospective study, we aimed to identify metabolic and genetic determinants of MTX toxicity. One hundred and thirty-four Dutch pediatric ALL patients were treated with four high infusions MTX (HD-MTX: 5 g m(-2)) every other week according to the DCOG-ALL-10 protocol. Mucositis (National Cancer Institute grade ⩾ 3) was the most frequent occurring toxicity during the HD-MTX phase (20%) and occurred especially after the first MTX course. Mucositis was not associated with plasma MTX, plasma folate or plasma homocysteine levels. Patients with mucositis had higher erythrocyte folate levels at the start of protocol M than patients without mucositis (median 1.4 vs 1.2 µmol l(-1), P<0.008), this could reflect an increased MTX uptake in mucosal cells of patients with mucositis. From 17 single-nucleotide polymorphisms in the MTX pathway, only patients with the wild-type variant of rs7317112 SNP in the ABCC4 gene had more mucositis (AA (39%) vs AG/GG (15%), P=0.016). We found no evidence that erythrocyte folate levels mediate in the association between the rs7317112 and mucositis.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Methotrexate/adverse effects , Methotrexate/therapeutic use , Mucositis/chemically induced , Mucositis/genetics , Polymorphism, Single Nucleotide/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Antimetabolites, Antineoplastic/adverse effects , Child , Child, Preschool , Erythrocytes/metabolism , Female , Folic Acid/metabolism , Genotype , Humans , Infant , Male , Multidrug Resistance-Associated Proteins/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Prospective Studies
7.
Eur J Pain ; 16(6): 849-59, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22337471

ABSTRACT

GRT9906 is an investigational novel compound with µ-opioid receptor agonism and inhibition of noradrenalin/serotonin re-uptake. In this randomized, double-blind, placebo-controlled, three-way cross-over trial in painful polyneuropathy, the efficacy and safety of GRT9906 was assessed and compared with tramadol. During 4-week treatment periods, daily oral doses of either GRT9906 120-240 mg, or placebo, or tramadol 200-400 mg were given. These were separated by 1-week washout periods. The primary endpoint was the average pain intensity (average of daily current pain intensity over the last 3 days of each treatment period rated on a 0 to 10-point numeric rating scale). One hundred seventeen patients were enrolled and 64 were randomized to one of six treatment sequences. Forty-seven patients qualified for the per protocol analysis. GRT9906 reduced average pain intensity by 2.1 points compared with a reduction of 0.6 points on placebo (p < 0.0001) and 2.4 points on tramadol. GRT9906 also improved scores on the sleep problem scale and the neuropathic pain symptom inventory and scored better than placebo on the patient global impression of change. Numbers needed to treat to obtain one patient with more than 50% pain relief was 3.9 (95% CI 2.4-11.5) for both GRT9906 and tramadol. The most frequently reported adverse events were nausea, fatigue, constipation and sleep disorder for GRT9906 and tramadol. Four patients dropped out due to adverse events during both GRT9906 and tramadol treatment and two dropped out during placebo treatment. In conclusion, in painful polyneuropathy, GRT9906 demonstrated analgesic efficacy with a magnitude of effect comparable with tramadol and was well tolerated.


Subject(s)
Analgesics, Opioid/administration & dosage , Diabetic Neuropathies/drug therapy , Dimethylamines/administration & dosage , Neuralgia/drug therapy , Phenols/administration & dosage , Polyneuropathies/drug therapy , Tramadol/administration & dosage , Administration, Oral , Adult , Aged , Analgesics, Opioid/adverse effects , Dimethylamines/adverse effects , Female , Humans , Male , Middle Aged , Phenols/adverse effects , Tramadol/adverse effects , Treatment Outcome
8.
Ned Tijdschr Geneeskd ; 156(1): A3981, 2012.
Article in Dutch | MEDLINE | ID: mdl-22217307

ABSTRACT

BACKGROUND: Sternal tumours in childhood are rare and alarming. These can be differentiated into benign and malignant tumours. This differentiation is important for the prevention of unnecessary diagnostic testing. CASE REPORT: An 11-month-old girl was seen at the Emergency Department for an acute sternal swelling without obvious trauma or fever. There were no other symptoms or abnormalities found on physical examination. An ultrasound revealed a typical 'dumb bell' sign. This finding, in combination with the clinical picture, indicated a 'self-limiting sternal tumour of childhood' (SELSTOC). Because of this diagnosis, the continuation of further examinations and treatment was abandoned and an expectative course was followed. The swelling completely disappeared within a few weeks. CONCLUSION: SELSTOC is a benign swelling on the sternum occurring in childhood, probably caused by aseptic inflammation. Its acute presentation is alarming and leads to over-diagnosing. However, the combination of the typical clinical presentation and the characteristic ultrasonographic dumb-bell sign justifies an expectative course. The abnormality resolves spontaneously within 6 months.


Subject(s)
Bone Neoplasms/diagnostic imaging , Sternum/pathology , Bone Neoplasms/diagnosis , Female , Humans , Infant , Sternum/diagnostic imaging , Ultrasonography , Watchful Waiting
9.
Atherosclerosis ; 220(1): 219-22, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22035982

ABSTRACT

OBJECTIVE: Stress and heart failure are associated with increased systemic levels of chromogranin A (CGA). Here we analyzed the effects of marathon running on systemic CGA levels and the association with cardiac burden and stress. METHODS: We recruited 47 lean and obese runners for a 10week training program aiming at running a marathon. Heart rates, individual fitness and marathon finishing times were monitored. CGA, proBNP and troponin T levels were analyzed by ELISA. RESULTS: We found a significant increase of CGA (+51%; p<0.01) in lean runners after marathon. The obese group showed the highest troponin T (0.22ng/ml; p<0.01) and proBNP (176.6ng/ml; p<0.01) levels. There were no correlations between proBNP, troponin T and CGA. An inverse correlation (r=-0.45; p<0.01) was found between CGA and finishing times. CONCLUSION: Marathon running is associated with increased CGA levels. However, this does not seem to reflect cardiac burden but rather marathon induced stress.


Subject(s)
Chromogranin A/blood , Heart Rate , Obesity/blood , Physical Endurance , Stress, Physiological , Adiposity , Biomarkers/blood , Enzyme-Linked Immunosorbent Assay , Germany , Humans , Natriuretic Peptide, Brain/blood , Obesity/physiopathology , Physical Fitness , Running , Time Factors , Troponin T/blood , Up-Regulation
10.
Ann Oncol ; 23(6): 1626-32, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22048153

ABSTRACT

BACKGROUND: Aim of this study was to investigate the long-term endocrine effects of treatment of childhood non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: A single-center cohort of 84 survivors (22 females) was included in this retrospective study. Median age was 21 years (9-40 years) and time after cessation of therapy 12 years (4-30 years). Height, weight, percentage fat, lean body mass (LBM), bone mineral content (BMC), bone mineral density of total body (BMD(TB)) and bone mineral density of lumbar spine (BMD(LS)) were measured. Thyroid-stimulating hormone (TSH), free thyroxin (fT4), insulin-like growth factor-1 (IGF-1), inhibin B and anti-müllerian hormone (AMH) levels were measured. Results were compared with Dutch controls. RESULTS: Height was lower in survivors [mean standard deviation score (SDS) -0.36, P = 0.002], but further analysis showed that shorter stature was already present at diagnosis (mean SDS -0.28, P = 0.023). Body mass index, percentage fat, BMC, BMD(TB) and BMD(LS) were not different from controls. LBM was lower in survivors (mean SDS -0.47, P = 0.008). TSH, fT4 and IGF-1 were normal in all survivors. Three of 20 adult females had low AMH levels and 23 of 42 adult males had low inhibin B levels. CONCLUSIONS: Twelve years after cessation of treatment, NHL survivors did not develop adiposity, osteoporosis or thyroid disease. Male survivors may be at risk for infertility.


Subject(s)
Antineoplastic Agents/adverse effects , Hormones/blood , Lymphoma, Non-Hodgkin/drug therapy , Survivors , Adolescent , Adult , Antineoplastic Agents/therapeutic use , Body Composition , Body Weights and Measures , Bone Density , Case-Control Studies , Child , Child, Preschool , Endocrine System/drug effects , Female , Follow-Up Studies , Humans , Lumbar Vertebrae/diagnostic imaging , Lymphoma, Non-Hodgkin/blood , Male , Radiography , Young Adult
11.
Bone ; 48(3): 571-7, 2011 Mar 01.
Article in English | MEDLINE | ID: mdl-20955826

ABSTRACT

BACKGROUND: This study aims to identify folate-metabolism-related genetic risk factors for low bone mineral density (BMD) during/after pediatric acute lymphoblastic leukemia (ALL) treatment. PATIENTS AND METHODS: We investigated the influence of methylenetetrahydrofolate reductase (MTHFR 677C > T and 1298A > C) and methionine synthase reductase (MTRR 66A > G) single nucleotide polymorphisms (SNPs) on total body BMD (BMD(TB)) and lumbar spine BMD (BMD(LS)) in 83 patients. Homocysteine, folate and vitamin B12 were determined. BMD was measured repeatedly using dual-energy X-ray absorptiometry in patients ≥ 4 years (n = 68). RESULTS: Carriers of the MTHFR 677 T-allele showed a lower baseline BMD(TB) than non-carriers (-0.38 SDS vs. +0.55 SDS, p = 0.01) and BMD(TB) remained lower during/after treatment. MTHFR 677C>T did not influence treatment-related loss of BMD(TB) (p = 0.39). The MTRR 66 G-allele carriers showed a trend towards a lower BMD(TB) compared with non-carriers. Combining these two SNPs, patients carrying ≥ 2 risk alleles had a significantly lower BMD(TB) (-1.40 SDS) than patients with one (-0.80 SDS) or no risk alleles (-0.31 SDS). Although carriers of the MTHFR 1298A > C had higher homocysteine levels, this SNP was not related to BMD(TB). BMD(LS) of carriers was similar to non-carriers of the investigated SNPs. CONCLUSIONS: The MTHFR 677C>T SNP and the MTRR 66A >G SNP were identified as determinants of impaired BMD(TB) in childhood ALL patients.


Subject(s)
Bone Density/genetics , Ferredoxin-NADP Reductase/genetics , Germ Cells/metabolism , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Polymorphism, Single Nucleotide/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/enzymology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Absorptiometry, Photon , Adolescent , Biomarkers, Tumor/genetics , Case-Control Studies , Child , Child, Preschool , Folic Acid/metabolism , Fractures, Bone/complications , Fractures, Bone/genetics , Genotype , Homocysteine/metabolism , Humans , Infant , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnostic imaging , Prospective Studies , Vitamin B 12/metabolism
12.
Ann Oncol ; 22(2): 472-8, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20699277

ABSTRACT

BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) is characterized by seizures, headaches, altered mental status, cortical blindness and typical transient lesions on magnetic resonance imaging. PATIENTS AND METHODS: We describe seven childhood cancer patients with clinical and radiological symptoms of PRES, and reviewed all well-documented PRES cases reported during childhood cancer treatment. RESULTS: Fifty-six children with PRES, including our 7 cases, were identified in the literature. Mean age at onset was 9 (range: 2-17) years. Primary diagnoses were acute lymphoblastic leukemia (n = 31), acute myeloid leukemia (n = 5), non-Hodgkin lymphoma (n = 7) and solid tumors (n = 13). PRES patients presented with seizures (n = 50), altered mental status (n = 20), visual disturbances (n = 24) and/or headaches (n = 17). PRES was associated with hypertension in 49 patients. About 86% of the patients had both clinical and radiological reversible symptoms. Four patients developed epilepsy, in one patient ataxia remained and one patient had a persistent mydriasis. CONCLUSION: Although PRES has predominantly been described in leukemia patients, it occurs in children with solid tumors as well. Hypertension seems to be the most important trigger for the occurrence of PRES during childhood cancer treatment. Seizures are the most common accompanying sign. Symptoms and radiological findings normalize in ∼90% of the cases, but in 10% neurological symptoms remain.


Subject(s)
Hypertensive Encephalopathy/etiology , Neoplasms/complications , Adolescent , Child , Child, Preschool , Cohort Studies , Female , Humans , Hypertensive Encephalopathy/diagnosis , Magnetic Resonance Imaging , Male
13.
Clin Nephrol ; 74(6): 474-9, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21084052

ABSTRACT

Kidney disease is a rare complication of Campylobacter jejuni (C. jejuni) enteritis. We here present the case of an 18-year-old male patient with crampy abdominal pain, vomiting, diarrhea, and fever. Three weeks later urinalysis revealed mild proteinuria and hematuria and a marked raise in serum creatinine was observed. Renal biopsy demonstrated acute endocapillary glomerulonephritis with mesangial IgM (immunoglobuline M) deposits. Extensive workup revealed no signs of skin or joint disease, thus excluding Henoch-Schönlein purpura. Due to persistent abdominal discomfort further gastro-enterological tests were performed and eventually Campylobacter jejuni was isolated from the patient's feces. In the absence of other precipitating factors for renal diseases we presumed an association between the bacterial infection and this postinfectious glomerulonephritis. Over a time period of 6 months the patient's kidney function normalized completely. However, long-term prognosis remains unclear. In addition to the case report, we conducted a review of the literature with results underlining Campylobacter jejuni's potential to trigger various types of immune mediated kidney diseases.


Subject(s)
Campylobacter Infections/microbiology , Campylobacter jejuni/pathogenicity , Enteritis/microbiology , Glomerular Mesangium/immunology , Glomerulonephritis/etiology , Adolescent , Biopsy , Campylobacter Infections/complications , Campylobacter Infections/immunology , Campylobacter jejuni/immunology , Diagnosis, Differential , Enteritis/complications , Enteritis/immunology , Feces/microbiology , Glomerular Mesangium/pathology , Glomerulonephritis/immunology , Glomerulonephritis/pathology , Humans , Immunoglobulin M/analysis , Male , Predictive Value of Tests
14.
Leukemia ; 24(12): 2014-22, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20861909

ABSTRACT

Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW7 is a frequent phenomenon in T-cell acute lymphoblastic leukemia (T-ALL). We retrospectively investigated the relevance of NOTCH1/FBXW7 mutations for pediatric T-ALL patients enrolled on Dutch Childhood Oncology Group (DCOG) ALL7/8 or ALL9 or the German Co-Operative Study Group for Childhood Acute Lymphoblastic Leukemia study (COALL-97) protocols. NOTCH1-activating mutations were identified in 63% of patients. NOTCH1 mutations affected the heterodimerization, the juxtamembrane and/or the PEST domains, but not the RBP-J-κ-associated module, the ankyrin repeats or the transactivation domain. Reverse-phase protein microarray data confirmed that NOTCH1 and FBXW7 mutations resulted in increased intracellular NOTCH1 levels in primary T-ALL biopsies. Based on microarray expression analysis, NOTCH1/FBXW7 mutations were associated with activation of NOTCH1 direct target genes including HES1, DTX1, NOTCH3, PTCRA but not cMYC. NOTCH1/FBXW7 mutations were associated with TLX3 rearrangements, but were less frequently identified in TAL1- or LMO2-rearranged cases. NOTCH1-activating mutations were less frequently associated with mature T-cell developmental stage. Mutations were associated with a good initial in vivo prednisone response, but were not associated with a superior outcome in the DCOG and COALL cohorts. Comparing our data with other studies, we conclude that the prognostic significance for NOTCH1/FBXW7 mutations is not consistent and may depend on the treatment protocol given.


Subject(s)
Cell Cycle Proteins/genetics , F-Box Proteins/genetics , Mutation , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics , Prednisone/therapeutic use , Receptor, Notch1/genetics , Ubiquitin-Protein Ligases/genetics , Child , F-Box-WD Repeat-Containing Protein 7 , Female , Gene Rearrangement , Homeodomain Proteins/genetics , Humans , Male , Treatment Outcome
16.
Pediatr Blood Cancer ; 55(1): 81-4, 2010 Jul 15.
Article in English | MEDLINE | ID: mdl-20213849

ABSTRACT

BACKGROUND: Because a sternal mass is often alarming, it is important to identify the clinical features of benign processes. PROCEDURE: Data on clinical presentation, diagnostics, treatment and outcome of pediatric patients presenting with a sternal tumor between 2001 and 2009 were collected from medical records. RESULTS: Among the 1,700 children who were referred to our pediatric-oncology center, 14 presented with a rapidly growing sternal mass. All patients (10 males) were Caucasian and median age was 16 (range: 7-50) months. Reported symptoms were local pain (n = 7) and/or raised body temperature (n = 5). No major preceding traumas were reported. Physical examination revealed solid tumors with a median diameter of 3 (range: 1-4.5) cm in a pre-sternal/para-sternal location. Half of the patients showed red/blue discoloration of the skin. On radiology, dumbbell-shaped lesions extended to the area behind the sternal bone, involving the cartilage, leading to increased distance between ossification centers. Histopathology at diagnosis was available from five patients and showed aspecific chronic or acute inflammation (n = 4) and a reactive osteochondromatous lesion (n = 1). Laboratory infection parameters were not/only slightly raised and microbiologic cultures were negative in all patients. All tumors decreased in size within 1 month, in both patients with and without antibiotics. On physical examination the tumors disappeared within 6 months. CONCLUSIONS: This study reports 14 young children with a rapidly growing sternal mass due to aseptic inflammation, that we named self-limiting sternal tumor of childhood (SELSTOC). To prevent invasive diagnostic interventions and unnecessary treatment, we advocate a wait-and-see approach with close follow-up in the first weeks.


Subject(s)
Bone Neoplasms/diagnosis , Sternum/pathology , Anti-Bacterial Agents/therapeutic use , Bone Neoplasms/drug therapy , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Male , Retrospective Studies , Sternum/drug effects , Treatment Outcome
17.
Z Gastroenterol ; 48(2): 274-88, 2010 Feb.
Article in German | MEDLINE | ID: mdl-20119895

ABSTRACT

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death in the world. The majority of HCCs develops on the basis of a chronic liver disease. This often complicates diagnosis and therapy. Non-invasive diagnostic criteria are based on dynamic imaging techniques and the serum level of AFP (alpha-fetoprotein). When evaluating HCC patients for therapy, besides tumor burden and localisation, the therapeutic evaluation must also consider the general condition of the patient and his/her liver function. For this purpose, the BCLC algorithm of the Barcelona Clinic for Liver Disease has proven helpful. Only one-third of the patients can be cured by resection, transplantation or local tumour ablation. In locally advanced cases transarterial procedures including transarterial chemoembolisation and radioembolisation are applied. HCC is a chemo-resistant tumour and chemotherapy is not accepted as standard of care in HCC. Sorafenib is the first systemic treatment with proven efficacy approved for the treatment of advanced and metastatic HCC. Interdisciplinary management of HCC patients is essential in order to provide every patient with the optimal therapy at his specific stage of disease.


Subject(s)
Carcinoma, Hepatocellular/therapy , Liver Neoplasms/therapy , Patient Care Team , Acetic Acid/administration & dosage , Antineoplastic Agents/therapeutic use , Brachytherapy , Carcinoma, Hepatocellular/diagnosis , Catheter Ablation , Chemoembolization, Therapeutic , Combined Modality Therapy , Contrast Media/administration & dosage , Ethanol/administration & dosage , Hepatectomy , Humans , Image Enhancement , Injections, Intralesional , Liver Neoplasms/diagnosis , Liver Transplantation , Magnetic Resonance Imaging , Palliative Care/methods , Practice Guidelines as Topic , Tomography, X-Ray Computed , Ultrasonography
18.
Pediatr Blood Cancer ; 53(1): 64-71, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19283791

ABSTRACT

BACKGROUND: Reduced bone mineral density (BMD), altered body composition, impaired motor performance and passive ankle dorsiflexion are side effects of acute lymphoblastic leukemia (ALL) treatment. We performed a randomized study investigating whether an exercise program could prevent these side effects. PROCEDURE: At diagnosis we randomized 51 ALL patients (median age: 5.4 years) into a group receiving a 2-year exercise program or a control group receiving standard care. BMD of total body (BMD(TB)), lumbar spine (BMD(LS)) and body composition were measured using dual energy X-ray absorptiometry, motor performance with Bayley Scales of Infant Development or Movement-ABC, and passive ankle dorsiflexion with a goniometer. The investigator was blinded to the randomization. RESULTS: Body fat increased equally during treatment in both groups. One year after cessation of therapy more rapid decline of excessive body fat was observed in the intervention group than in the controls (P = 0.01). Lean body mass, BMD(TB) and BMD(LS) of both groups decreased equally during treatment and increased equally thereafter. Both groups showed a similar decrease in passive ankle dorsiflexion and motor performance during treatment. Adherence to the intervention program varied considerably. Adherence to intervention: 11% of children exercised daily, 37% > once a week, 16% once weekly, 36% < once a week. CONCLUSIONS: The exercise program was not more beneficial than standard care in preventing reduction in BMD, motor performance and passive ankle dorsiflexion than standard care, most likely due to unsatisfactory compliance. Increased BMI and body fat in the intervention group normalized faster after cessation of chemotherapy.


Subject(s)
Bone Density , Bone Diseases, Metabolic/prevention & control , Exercise Therapy/methods , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Adolescent , Ankle/physiopathology , Anthropometry , Body Composition , Bone Diseases, Metabolic/etiology , Child , Child, Preschool , Female , Humans , Infant , Male , Motor Skills/classification , Range of Motion, Articular
19.
Internist (Berl) ; 48(8): 870-3, 2007 Aug.
Article in German | MEDLINE | ID: mdl-17605113

ABSTRACT

ACTH-independent macronodular bilateral adrenal hyperplasia (AIMAH) is a rare cause of endogenous Cushing's syndrome. Here, massive bilateral adrenal enlargement is accompanied by ACTH-independent hypercortisolism. The detection of ectopic hormone receptors which, according to a new concept, control the cortisol production in AIMAH, offers the opportunity of normalizing the hypercortisolism by pharmacologically influencing the receptor or its ligand. We here present the case of a 46 year old male patient. Using clinical and pharmacological tests we found evidence of ectopic receptors in the AIMAH. After suspicion was erroneously raised that a malignant lesion could be inside of the right adrenal mass, the decision was made to resect both adrenals instead of trying to treat the hypercortisolism by pharmacological means. This surgical approach (bilateral adrenalectomy) has been the standard way of treatment for AIMAH until the new concept of the ectopic receptors was developed.


Subject(s)
Adrenal Glands/pathology , Cushing Syndrome/diagnosis , Adrenalectomy , Adrenocorticotropic Hormone/blood , Cushing Syndrome/pathology , Cushing Syndrome/surgery , Diagnosis, Differential , Humans , Hydrocortisone/blood , Hyperplasia , Male , Middle Aged
20.
Medicina (B.Aires) ; 66(4): 332-334, 2006. ilus
Article in Spanish | LILACS | ID: lil-449012

ABSTRACT

Intracraneal manifestations of Hodgkin's Disease (HD) are extremely rare, with an estimated incidence rate of approximately 0.5%. They can be classified as: 1) treatment-related leucoencephalopathy, 2) central nervous system infections, 3) paraneoplasic syndromes and 4) intracraneal lymphomas, which could be sub-classified into intraparenchymal or intradural masses. We describe a case of a 40 year-old male with mixed cellularity type HD who developed neurological manifestations as relapsed disease. Magnetic resonance imaging suggested leptomeningeal metastases and atypical cells were found in cerebrospinal fluid. The patient died from progressive disease refractory to third line chemotherapy. There are less than 50 similar cases reported in the literature. We review the clinical features and differential diagnosis of leptomeningeal metastases in Hodgkin's disease.


Subject(s)
Adult , Humans , Male , Hodgkin Disease/pathology , Meningeal Neoplasms/secondary , Biopsy, Needle , Bleomycin/administration & dosage , Cyclophosphamide/administration & dosage , Cisplatin/administration & dosage , Cytarabine/administration & dosage , Diagnosis, Differential , Dacarbazine/administration & dosage , Hodgkin Disease/cerebrospinal fluid , Hodgkin Disease/drug therapy , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Fatal Outcome , Leukoencephalopathy, Progressive Multifocal/chemically induced , Leukoencephalopathy, Progressive Multifocal/pathology , Magnetic Resonance Imaging , Meningeal Neoplasms/cerebrospinal fluid , Prednisone/administration & dosage , Procarbazine/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Recurrence , Paraneoplastic Syndromes/pathology , Vinblastine/administration & dosage , Vincristine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...